Helicobacter pylori Infections – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Helicobacter pylori Infections – Drugs In Development, 2024 report and make more profitable business decisions.
Helicobacter pylori (H. pylori) infection occurs when the Helicobacter pylori (H. pylori) bacteria infect the stomach, typically during childhood. A leading cause of stomach ulcers, this infection is asymptomatic for many, with over half of the global population potentially affected. Recognition often arises when peptic ulcer symptoms manifest, prompting healthcare providers to test for H. pylori. Peptic ulcers, affecting the stomach (gastric ulcer) or the initial part of the small intestine (duodenal ulcer), are indicative of H. pylori involvement. Antibiotics form the primary treatment for H. pylori infection, emphasizing the importance of diagnosis and intervention in managing peptic ulcer complications.
The Helicobacter pylori Infections drugs in development market research report provide comprehensive information on the therapeutics under development for Helicobacter pylori Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Helicobacter pylori Infections and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Helicobacter pylori Infections | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 29 molecules, with 23 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Helicobacter pylori Infections therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Helicobacter pylori Infections pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Helicobacter pylori Infections treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Cinclus Pharma Holding ABCrestone Inc
EpiVax Inc
HK inno.N Corp
Iguana Biotechnology GmbH
IGY Immune Technologies & Life Sciences Inc
ImevaX GmbH
ImmunoBiology Ltd
Jiangsu Sinorda Biomedicine Co Ltd
Luoxin Pharmaceuticals Group Stock Co Ltd
Nexbiome Therapeutics
Recce Pharmaceuticals Ltd
RedHill Biopharma Ltd
SCG Cell Therapy Pte Ltd
Servatus Ltd
Shanghai High-Tech Bioengineering Co Ltd
Shanxi Kangbao Biological Product Co Ltd
Sichuan University
Spanish Foundation for Science and Technology
Takeda Pharmaceutical Co Ltd
TenNor Therapeutics Ltd
Trio Medicines Ltd
University of California San Diego
University of Florida
University of Illinois
University of Iowa
Xiamen Encheng Pharmaceutical Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Helicobacter pylori Infections reports